





RESEARCH ARTICLE

Synthetic PreImplantation Factor (sPIF) reduces inflammation and prevents preterm birth


Marialuigia Spinelli¹ , Céline Boucard¹ , Fiorella Di Nicuolo^{2,3}, Valerie Haesler¹, Roberta Castellani², Alfredo Pontecorvi^{2,4}, Giovanni Scambia^{2,5}, Chiara Granieri², Eytan R. Barnea^{6,7}, Daniel Surbek¹, Martin Mueller^{1†*}, Nicoletta Di Simone^{2,8‡*} 

1 Department of Obstetrics and Gynecology and Department of Biomedical Research, University Hospital Bern, University of Bern, Bern, Switzerland, **2** Università Cattolica del Sacro Cuore, Istituto di Clinica Ostetrica e Ginecologica, Roma, Italia, **3** International Scientific Institute Paolo VI, Università Cattolica Del Sacro Cuore, A. Gemelli University Hospital, Rome, Italia, **4** U.O.C di Endocrinologia e Diabetologia, Dipartimento di Scienze Gastroenterologiche, Endocrino-Metaboliche e Nefro-Urologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia, **5** U.O.C. di Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia, **6** The Society for The Investigation of Early Pregnancy (SIEP), Cherry Hill, NJ, United States of America, **7** BioIncept LLC, Cherry Hill, NJ, United States of America, **8** Dipartimento di Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli IRCCS, U.O. C. di Ostetricia e Patologia Ostetrica, Roma, Italia

 These authors contributed equally to this work.

 These authors also contributed equally to this work.

* martin.mueller@insel.ch (MM); nicoletta.disimone@unicatt.it (NDS)



OPEN ACCESS

Citation: Spinelli M, Boucard C, Di Nicuolo F, Haesler V, Castellani R, Pontecorvi A, et al. (2020) Synthetic PreImplantation Factor (sPIF) reduces inflammation and prevents preterm birth. PLoS ONE 15(6): e0232493. <https://doi.org/10.1371/journal.pone.0232493>

Editor: Tamas Zakar, John Hunter Hospital, AUSTRALIA

Received: December 13, 2019

Accepted: April 15, 2020

Published: June 8, 2020

Copyright: © 2020 Spinelli et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: NDS and MM received an unrestricted fund from BioIncept. BioIncept provided sPIF. ERB is CSO of BioIncept. The specific roles of this authors are articulated in the 'author contributions' section. In addition, the following grants helped fund this research: Università Cattolica del Sacro Cuore (D1 2015: 70201356), Istituto Scientifico Internazionale, Paolo VI Institute, Università Cattolica del Sacro Cuore, Rome, Italy to NDS, and

Abstract

Preterm birth (PTB) is the leading cause of neonatal morbidity and mortality and spontaneous PTB is a major contributor. The preceding inflammation/infection contributes not only to spontaneous PTB but is associated with neonatal morbidities including impaired brain development. Therefore, control of exaggerated immune response during pregnancy is an attractive strategy. A potential candidate is synthetic PreImplantation Factor (sPIF) as sPIF prevents inflammatory induced fetal loss and has neuroprotective properties. Here, we tested maternal sPIF prophylaxis in pregnant mice subjected to a lipopolysaccharides (LPS) insult, which results in PTB. Additionally, we evaluated sPIF effects in placental and microglial cell lines. Maternal sPIF application reduced the LPS induced PTB rate significantly. Consequently, sPIF reduced microglial activation (Iba-1 positive cells) and preserved neuronal migration (Cux-2 positive cells) in fetal brains. In fetal brain lysates sPIF decreased IL-6 and INF γ concentrations. In-vitro, sPIF reduced Iba1 and TNF α expression in microglial cells and reduced the expression of pro-apoptotic (*Bad* and *Bax*) and inflammatory (*IL-6* and *NLRP4*) genes in placental cell lines. Together, maternal sPIF prophylaxis prevents PTB in part by controlling exaggerated immune response. Given the sPIF'FDA Fast Track approval in non-pregnant subjects, we envision sPIF therapy in pregnancy.

University Hospital Bern (2019-00431) to MS and MM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: NDS and MM received an unrestricted grant from BioIncept. ERB is CEO of BioIncept and sPIF is BioIncept proprietary. There are no patents, products in development or marketed products to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Introduction

Preterm birth (PTB) is currently the leading cause of childhood mortality under the age of five [1]. Spontaneous PTB accounts for approximately 70% of PTBs and strongly associated with inflammation/infection cascade [2]. Recent evidence suggest that the overall shift in the inflammatory environment, rather than the presence of individual microbial communities during microbiome disruption, contributes to spontaneous PTB [3]. In line with this notion, anti-microbial treatments have shown limited efficacy in reducing PTB risk [4]. Interestingly, an inflammatory insult contributes not only to the PTB risk but also to the risk of fetal mortality and morbidities. For example, chorioamnionitis is associated with higher rate of cerebral palsy, necrotising enterocolitis, and patent ductus arteriosus of the fetus [5–7]. Survivor of PTB have a higher incidence of cognitive and/or behavioral deficits such as sensory, learning/memory, language, attention deficits and hyperactivity, and autism spectrum disorder [8,9]. Together, proper control of an exaggerated inflammatory response should not only reduce the PTB incidence but also impact fetal morbidities such as brain injury [10,11].

In pregnancy, the immune system is complex and the set of pathogen recognition receptors: toll-like receptors (TLRs) are essential [4,12]. TLRs are activated by pathogen associated molecular patterns (PAMPs) resulting in activation of inflammatory cascades [13,14]. The bacteria derived major pro-inflammatory antigen lipopolysaccharide (LPS) serve as PAMPs and not surprisingly, the LPS-induced inflammation animal model is a frequently used and well-described model to study inflammation induced PTB [15]. Furthermore, LPS induces macrophage-derived tumor necrosis factor (TNF)- α production and interferon (INF)- γ secretion [16], which result in release of fetotoxic cytokines contributing to fetal long-term morbidities [17,18]. We postulate that PTB targeted prevention requires maternal and fetal immune control. A potent candidate is PreImplantation Factor (PIF) since PIF shapes the immune system during pregnancy [19,20].

PIF is a small 15-amino acid pregnancy derived peptide, which is secreted by the trophoblast/embryo [21,22]. Trophoblast invasion and endometrial receptivity resulting in proper embryo development and finally a favorable pregnancy outcome are in part the result of PIF secretion [21–29]. Mechanistically, PIF modulates immune responses [30,31], while reducing oxidative stress and protein misfolding [28,29]. Not surprisingly, a synthetic version of PIF (PIF analog: sPIF) was successfully tested in animal models of multiple immune disorders [32–38] and received a FAST-Track FDA approval (autoimmune diseases of non-pregnant subjects—clinicaltrials.gov, NCT02239562). Together, sPIF is a pregnancy derived peptide exerting immune-modulatory properties, which at least in part were TLR4 mediated [35,36]. As TLRs are essential during inflammatory PTB and sPIF modulates inflammation during pregnancy, we tested whether maternal sPIF pre-treatment is able to reduce the incidence of PTB and resulting immune responses.

Materials and methods

Animals and treatments

We synthesized synthetic PIF₁₅ (MVRKPGSANKPSDD) by solid-phase peptide synthesis (Peptide Synthesizer, Applied Biosystems) employing Fmoc (9-fluorenylmethoxycarbonyl) chemistry at Bio-Synthesis, Inc. (Lewisville, TX, USA) as previously published [20]. Briefly, we carried out final purification by reversed-phase HPLC and we verified the identity by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (amino acid analysis at >95% purity). sPIF was used for all experiments.

In order to mimic inflammatory PTB we used female Swiss mice (7–8 weeks old), which were paired with adult Swiss mice ($n = 55$) as previously published [20]. Briefly, we considered day 0 of gestation as the day of appearance of post-coitum vaginal plug. We housed animals in accordance with Ethics Committee and Veterinary Department guidelines. Prior to surgery, we assured acclimatization of all animals to the laboratory environment and we provided animals with food and water ad libitum. We used controlled conditions of light (12h light/12h dark) and temperature (23–25°C) for animal housing. We followed aseptic rodent survival surgery guidelines. We used 4 groups ($n = 55$ total) in our experimental protocol. We treated two groups of pregnant mice (14 each) with sPIF (1 µg/g mouse /day) using micro-osmotic pumps from day 0 until day 14 of gestation. The other two groups received phosphate buffered solution (PBS—200 µl; $n = 27$) from day 0 until day 14 of gestation. On day 14 of gestation, half of each group was injected with LPS (from *Escherichia Coli* serotype 0111:B4; Sigma-Aldrich, St Louis, MA USA; intra-peritoneum 300 µg/kg mouse in 200 µl PBS) or PBS (200 µl). Thus, we investigated the following 4 groups: Control ($n = 14$), sPIF ($n = 14$), LPS ($n = 13$), and LPS +sPIF ($n = 14$). Notably, in multiple animal studies the dosage of synthetic PIF was used previously [20,32,33,35,36,38]. We sacrificed mice on day 16 of pregnancy and dissected the uteri and fetuses. Briefly, pregnant mice were anesthetized via intraperitoneal injection of Ketamine and Xylazine (ketamine 80–100 mg/kg, xylazine 10–12.5 mg/kg) and sacrificed by cervical dislocation, the uteri were dissected and embryos were harvested. All the embryos were processed while alive embryos were immediately anesthetized by hypothermia (placing them on ice in a Petri plate). Embryos were decapitated with scissors and half of the brain tissue was removed and stored in formalin (10% neutral-buffered solution) or (the other half) frozen at -80°C for subsequent experiments.

We implanted micro-osmotic pumps as previously performed [20]. Briefly, we used intraperitoneal injection of Ketamine and Xylazine (ketamine 80–100 mg/kg, xylazine 10–12.5 mg/kg) in mice and once we detected loss of the righting reflex we proceeded with surgery. We implanted pumps subcutaneously on the back of mice by making a small cut in the mid-scapular region. After implantation the incision was closed with wound clip. After recovery from anesthesia, we monitored mice for several signs including bleeding, discomfort, or pain. If necessary, we used local anesthesia (lidocaine, 4 mg/kg, 0.4 ml/kg of a 1% solution).

Importantly, all used procedures followed the requirements of Commission Directive 86/609/EEC, which concern the protection of animals used for experimental and other scientific purposes. We acquired local ethical committee approval on preclinical studies [n° 5647/14 (A13 D)] from Università Cattolica del Sacro Cuore Roma, Italy.

ELISA assay

Once brain tissue was collected, we dissected fetal brains and measured cytokines in those lysates (3 brains per pregnant animal pooled; $n = 6$ –7 per group) by an enzyme-linked immunoassay (ELISA) according to manufacturer's instructions (USCN Life Science Inc. and Cloud-Clone Corp. Houston, TX, USA). Briefly, brain tissues were collected, washed with PBS, minced and lysed using Cell lysis Buffer (Cell Signaling Technology, Inc., Danvers, MA, USA) in the presence of protease inhibitors (Roche Diagnostics, Indianapolis, IN, USA), then were sonicated briefly and centrifuged for 20 minutes at $14000 \times g$ at 4°C . We measured the proinflammatory cytokines IL-6 and INF- γ as previously performed [20]. Briefly, we added samples or standard (100 µl) to each well coated with monoclonal anti-cytokine antibody. We incubated at 37°C for 2h, and washed the wells prior to incubation with a specific enzyme-linked polyclonal antibody, horseradish peroxidase. Then, we added tetramethylbenzidine substrate solution to each well, and the color developed in proportion to the amount of the

proteins bound in the initial step. We used the Titertek Multiscan plus Mk II plate reader (ICN Flow Laboratories, Irvine, CA) to measure the absorbance at wavelengths of 450 nm.

Placental and microglial cell culture

BV-2 microglia and BeWo placental culture: We purchased the semi-adherent mouse cell line BV-2 (ATL03001) from Banca Biologica e Cell Factory, Genoa, Italy. We used Roswell Park Memorial Institute (RPMI) 1640 with 10% FBS, 2 mmol/l GlutaMAX™, 100 units/ml penicillin, and 100 mg/ml streptomycin for cell expansion. We used mechanical vibrations and flushing with PBS in cells to detached the from culture plates. BeWo human choriocarcinoma cell lines were kindly provided by Prof. Christiane Albrecht (University of Bern) and cultured in expansion medium consisting of Dulbecco's modified Eagle's medium (DMEM)/F12 supplemented with 10% fetal bovine serum (FBS). In order to stimulate BV-2 and BeWo cells with LPS (or use sPIF), we seeded cells at density of 12'500 cells/cm² or 18'000 cells/cm² prior to incubation with LPS. We used 100 ng/ml LPS (Sigma-Aldrich) for 6h (BeWo) and 24 h (BV2) and after stimulation, we treated cells with sPIF (concentrations: 100, 200, or 300 nM for 4 hours). Cells cultured without the addition of sPIF served as controls.

Cell counts: We collected media from BV2 cell plates, and adherent BV2 cells through trypsinization. Both media and cells were centrifuged at 2500 rpm for 5 min at 4°C. The supernatant was removed and the cell pellet was resuspended in 1 ml of media. A small aliquot of the media was diluted with PBS and mixed with trypan blue exclusion dye. Viable and nonviable cells were counted on a hemocytometer.

Gene quantification by real-time polymerase chain reaction (RT-PCR)

We used the QIAshredder and the Allprep DNA/RNA/Protein Mini Kit according to the manufacturer's protocol (Qiagen, Hilden, Germany) for RNA isolation. Briefly, RNA concentration was measured using a NanoVue Plus™ spectrophotometer (Biochrom, Holliston, MA, USA). The RNA purity was assured by measuring the 260 nm/280 nm ratio. We considered a ratio between 1.8 and 2.1 as pure and high-quality RNA. Up to 3 µg RNA reverse transcribed was used in combination with the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific). Gene expression in cells was quantified using real-time reverse transcription polymerase chain reaction (RT-PCR). Following gene were tested: Iba1, TNFα, BAD, BAX, IL6 and NLRP4 by real-time RT-PCR. We used following PCR cycling program: 2 min at 50°C followed by 10 min at 95°C, and finally 45 cycles of 15 s at 95°C and 1 min at 60°C. We used a QuantStudio™ 7 Flex Real-Time PCR System (Thermo Fisher Scientific). For housekeeping gene glyceraldehyde-3-phosphate dehydrogenase as endogenous control was used. Notably, we adopted primer and probe sequences using RT Primer Database and used the QuantStudio™ Real-Time PCR software (Thermo Fisher Scientific) for analysis. We calculated gene expression using the 2^{−ΔΔCt} method relative to untreated cells. We used following primers:

1. Iba1 (GE assay ID: Rn01525937_g1, Thermo Fisher Scientific, US)
2. TNFα (GE assay ID: Dr03126850_m1, Thermo Fisher Scientific, US)
3. BAD (GE assay ID: Hs00188930_m1, Thermo Fisher Scientific, US)
4. BAX (GE assay ID: Hs00180269_m1, Thermo Fisher Scientific, US)
5. IL6 (GE assay ID: Hs00174131_m1, Thermo Fisher Scientific, US)
6. NLRP4 (GE assay ID: Hs00370499_m1, Thermo Fisher Scientific, US)

Immunohistochemistry

We used a set of fetal brains for Elisa testing (see above) and the other fetal brains for immunohistochemistry [35,36]. Briefly, after brain removal we fixed the tissue in formaldehyde solution (4%) for 2–4 hours at RT followed by 4°C for a total time of 24–48 hours. Fixed brains were embedded in paraffin and finally sectioned into 7µm slices. Following a de-paraffinization procedure, we used a pressure cooker for 12 minutes and retrieved the target citrate buffer (10 mM; pH 6.0). We used 0.1% Tween-20/PBS for washing and 10% goat serum/1% bovine albumin/1% Triton-x/PBS for blocking slides. We incubated slides overnight: first incubation at 4°C with mouse monoclonal antibodies specific for the Cut Like Homeobox 2 antigen (Cux2, Bioss, BS-11832R, 1:100) or ionized calcium-binding adapter molecule 1 (Iba1, Abcam, AB5076, 1:100). Following first antibody incubation, we washed the slides in 0.1% Tween-20/PBS (3x 5min). To highlight both microglial cells and progenitor neuronal cells, slides were incubated for one hour at RT with peroxidase-labeled secondary antibody (DAKO, Glostrup, Denmark, 1:100), as a second antibody, then washed in PBS (4x5 min). Finally we used DAB + chromogen application in buffer substrate according to the manufacturer's instructions (DAKO EnVision+ System-HRP (DAB), K4007). We rinsed the slides in dH₂O. We used 11 minutes Cresyl violet (Nissl body staining for neuronal structure and gross brain morphology) for counterstaining and a series of ethanol baths (95% > 100%) and xylene for dehydration. Slides were mounted with Eukitt (Sigma-Aldrich, St. Louis, MO).

Assessment of neuronal and microglial positive cells were performed in the region of interest (ROI). We defined ROI as cortical area between the rhinal sulcus and the cingulum (CC; contains cerebral white matter) and developing dentate gyrus germinal matrix (DGm) as injury in these regions cause distinctive neuropathological alterations [35,39–42]. All images of immunohistochemical stainings were obtained with a Zeiss based microscope (Pannoramic, 3CCD camera Hitachi HV-F22CL 1,4MP and Zeiss AxioCam MRm monochrome camera) equipped with a digital camera. We used 40× or 60× objective to acquire images for ROI evaluation. Six consecutive coronal sections per animal and for each specific immunostaining were acquired by an independent observer blinded to the experimental conditions. We analyzed and reconstructed the images using Image J (US National Institutes of Health).

Quantification and statistical analysis

We performed all quantifications including the manual cell counts in a blinded manner. We counted Cux2 and Iba1 positive cells in the ROI (see above) as previously reported [40,43,44]. We determined the number of cells by unbiased counting of positive cells [43].

Statistical Analysis: We present the results as the mean ± standard deviation (mean±SD). We calculated the PTB significance using Chi-square test. We used one-way analysis of variance (ANOVA) followed by a post-hoc test (Bonferroni test) for additional analysis. We determined statistical significance at $p < 0.05$.

Results

Synthetic PIF prevents PTB and reduces inflammation (in-vitro)

Given PIF's pro-pregnancy properties in vitro [23] and in vivo [20], we examined synthetic PIF's properties in a well-established murine model of LPS induced PTB (Fig 1A) [45,46]. This model provides optimal reproductive outcome and it reflects the inflammatory response after a microbial challenge(s) during pregnancy. We administered LPS on day 14 of gestation and analyzed pregnancy outcomes 2 days later, which mimic early inflammatory insult during pregnancy (expected time of delivery day 18–22). Notably, we used sPIF in a maternal




Fig 1. Experimental setup and fetal outcomes after LPS induced insult and synthetic PIF pre-treatment. A: Experimental setup: We used 4 experimental groups. Control group received PBS (200 μ l/day) on postnatal day 14 (P14) instead of LPS. Synthetic PIF group received synthetic PIF (1 μ g/g mouse/day) from P0-14 and PBS on P14 (instead of LPS). LPS group received LPS (0.1 μ g/g mouse) on P14 and LPS/sPIF group received both LPS and synthetic PIF (same as above). B: The incidence of PTB. C: In fetal brain lysates maternal sPIF pre-treatment reduces pro-inflammatory cytokines IL-6 and INF- γ . *** $p < 0.001$. sPIF: synthetic PreImplantation Factor; LPS: Lipopolysaccharides. PTB: Preterm Birth. Data are mean \pm SD.

<https://doi.org/10.1371/journal.pone.0232493.g001>

prophylactic regime as it reflects potential clinical application (Fig 1A). We detected an increase in prematurity rate after LPS application and sPIF pretreatment reduced this PTB rate significantly (Fig 1B; compare LPS to LPS+sPIF groups). This observation is in line with previous reports of sPIF preventing LPS induced fetal loss [20]. We decided to focus on fetal brains next as an inflammatory insult during pregnancy may result not only in PTB but also in an increased risk of impaired fetal brain development [2,8,9]. We measured IL-6 and INF- γ levels in fetal brain lysates as they impact brain development [5]. For example, IL-6 as a pleiotropic and variably glycosylated cytokine and INF- γ as an immune-regulatory cytokine were reported to impact both PTB and neonatal brain injury [47,48]. Expectantly, we detected increased expressions of IL-6 and INF- γ in fetal brains after maternal LPS application (Fig 1C: compare

red to black bars). Maternal sPIF pre-treatment resulted in prevention of pro-inflammatory cytokine (IL-6 and INF- γ) production (Fig 1C: compare green-red striped to red bars). This observation is in line with previous reports of sPIF reducing inflammatory responses in fetal [35,36] and adult brains [33,49,50].

Synthetic PIF reduces the inflammatory response (in-vivo)


Since sPIF modulated inflammation during pregnancy (Fig 1) [20], we decided to test sPIF in challenged placental cells next. We chose to test pro-inflammatory (IL-6 and NLRP4) and pro-apoptotic (*Bad* and *Bax*) genes as they contribute to pregnancy complications such as PTB [5,20,51,52]. We detected moderate changes after sPIF-only treatment (Fig 2A and 2B; compare green to black bars). Therefore, we pretreated cells with LPS (to mimic inflammatory insult) and used sPIF again. LPS application resulted in increased expression of pro-apoptotic (*Bad* and *Bax*) and pro-inflammatory (IL-6 and NLRP4) genes (Fig 2A and 2B; compare red to black bars). Importantly, sPIF reduced these responses significantly (Fig 2A and 2B; compare green-red striped to red bars). Notably, sPIF's anti-inflammatory and anti-apoptotic effects (Fig 2A and 2B) are in line with previous reports [20,35,36]. Since sPIF modulated the inflammatory responses in the placenta (Fig 2A and 2B) and in fetal brain lysates (Fig 1C), we aimed to test the effect on microglial cells next [35,36]. As seen in Fig 2C, LPS challenge (mimics inflammatory insult) induced the gene expression of ionized calcium binding adaptor molecule 1 (*Iba1*) and tumor necrosis Factor α (TNF- α). Notably, *Iba1* and TNF- α are well-defined markers of inflammation in the brain and sPIF modulated *Iba1* previously [33,35,53]. sPIF treatment prevented the LPS induced *Iba1* and TNF- α expression (Fig 2C: compare green-red striped to red bars). Together, maternal sPIF pre-treatment reduces the incidence of inflammatory PTB in pregnant animals (Fig 1), which in part is due to reduced inflammatory responses (Fig 2). We aimed to investigate the specific effects in fetal brains next.

Synthetic PIF prevents inflammatory responses in fetal brain

In the central nervous system, microglia (macrophage lineage) represent both the target and source of injury [35,54,55]. Not surprisingly, decreased microglial activation has been associated with reduced cerebral response to injury and restored number of neurons [35,44,56]. The pyramidal neurons are a central part of the mammalian cerebral cortex, which is a six-layered structure [57]. Neurons migrate in a well-defined inside-out fashion. Deep-layers neurons arise and migrate first followed by upper-layers neurons, which are born and migrate later [58]. Notably, in immature brains cortical neurons are especially susceptible to inflammation, injury results in altered cortical development, and *Cux2* represents a valid marker of migrating superficial layer neuros [36,59,60]. We evaluated fetal microglial (*Iba1* positive cells) and neuronal (*Cux2* positive cells) cells after LPS-induced PTB (experimental setup: Fig 1A). We focused on evaluating cortical regions between the rhinal sulcus and the cingulum (CC) and developing dentate gyrus germinal matrix (DGm) as injury in these regions cause distinctive neuropathological alterations [35,39–42]. We detected increased activation of fetal microglia after the inflammatory insult (Fig 3A and 3C; compare Injury to Sham panels and red to black bars), which were abrogated by maternal sPIF pre-treatment (Fig 3A and 3C, compare Injury +sPIF to Injury panels and green-red striped to red bars). Further, in sPIF-treated animals we detected morphological changes in *Iba1* positive microglia. *Iba1* positive cells shifted from predominantly amoeboid to ramified state (Fig 3A, compare red to green arrowhead indicated cells). These results are consistent with a view that sPIF reduces cerebral inflammation [35,49]. To evaluate sPIF's impact on neuronal cells we chose *Cux2*. *Cux2* is a marker of migrating superficial layer neurogenic progenitors [35,36,41,59,60]. We detected decreased number of


A.

Placental Cell Line (BeWo) – RT-qPCR



B.

Placental Cell Line (BeWo) – RT-qPCR



C.

Microglial Cell Line (BV2) – RT-qPCR




Fig 2. Inflammatory responses. A and B: Placental cell lines were treated sPIF (200nM), LPS, or LPS + increasing sPIF dose (100–300 nM). We analysed pro-inflammatory (A) pro- apoptotic (B) genes using RT-qPCR. C: Microglial cell lines (BV2) were treated with sPIF (200–300 nM) in the presence of LPS. We analysed pro-inflammatory genes Iba1 and TNF- α . * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$. sPIF: synthetic PreImplantation Factor; LPS: Lipopolysaccharides. Data are mean \pm SD.

<https://doi.org/10.1371/journal.pone.0232493.g002>

Cux2 neurons in both cortex and germinal matrix (Fig 3B and 3D; compare Injury to Sham panels and red to black bars). Importantly, sPIF pre-treatment prevented Cux2 neuronal loss (Fig 3B and 3D; compare Injury+sPIF to Injury panels and green-red striped to red bars), which is in line with the reduced inflammatory response (Fig 3A and 3C). These results extend previous reports of PIF's neuroprotective properties [33,35,36,49,50]. Together, our results




Fig 3. Inflammation and neuronal migration in fetal brains. Representative images of inflammatory markers (A: microglia: Iba1) and neuronal progenitors (B: migrating neurons: Cux2) after LPS-induced insult and maternal sPIF pre-treatment. A: We detected increased number of Iba1 positive cells in fetal DGm and CC regions of LPS challenged animals. Maternal sPIF pre-treatment reduced the number of Iba1 positive cells. Green arrowheads indicate examples of amoeboid and red arrows of ramified microglial cells. B: We detected reduced number of Cux2 positive cells in fetal DGm and CC regions of LPS challenged animals. Maternal sPIF pre-treatment reduced the loss of Cux2 neurons. Red arrowheads indicate examples of Cux2 positive neurons. C and D: Analyses of inflammatory response (Iba1 positive cells) and neuronal migration (Cux2 positive cells) in fetal brains after maternal inflammatory challenge. sPIF: synthetic PreImplantation Factor; LPS: Lipopolysaccharides. DGm: dentate gyrus germinal matrix. CC: cerebral cortex. Data are mean \pm SD. Scale bar: 20 μ m.

<https://doi.org/10.1371/journal.pone.0232493.g003>

provide evidence that maternal sPIF pre-treatment reduces PTB incidence and reduces the inflammatory insult both in the placenta and fetal brain. Given sPIF FAST-Track FDA approval for clinical trial in autoimmune diseases of non-pregnant subjects (clinicaltrials.gov, NCT02239562), prophylactic sPIF treatment in pregnancy can be envisioned.

Discussion

Our current findings are in line with the notion of PIF's trophic and protective effects during pregnancy [20,21]. Maternal sPIF pre-treatment provided reduction of inflammatory response to a microbial-like challenge (Figs 1 and 2) to both mother and the fetus. This is important as during PTB the inflammatory insult may effect both the maternal and fetal compartment. Indeed, vaginal dysbiosis may increase susceptibility to pregnancy complications in part by triggering or propagating host inflammatory responses [4,12]. Therefore, the predisposition to PTB may be the result of an overall shift towards an inflammatory environment rather than the presence of individual microbial community [61]. In this case, the modulation of maternal immune-responses, such as sPIF provides, would be an attractive strategy not only in PTB but in other diseases such intrauterine growth restriction or early recurrent pregnancy loss [28,31,62]. Studies addressing fetal growth are being initiated but beyond the scope of this manuscript.

In the fetal brain, sPIF modulated not only the inflammatory response (Figs 1C and 3A) but also neuronal precursors (Fig 3B and 3D). This observation is in line with previous reports of sPIF protecting newborn and adult brains [33,35,36,49,50]. Here, we provide evidence that this effect expands to the fetal period, suggesting a potential effect on neuronal migration/development. Currently, the only interventions known to reduce the burden of brain injury in the term born infants is hypothermia. Hypothermia is associated reduces death and disability in children subjected to perinatal asphyxia significantly [63]. However, approximately half of infants die or develop significant neurological disability despite hypothermia treatment. In the preterm-born population, the antenatal magnesium sulfate prophylaxis (< 30 weeks of gestation) reduces morbidities and mortality rate at 2-years of age. However, magnesium sulfate prophylaxis may result in maternal intoxication and long-term neurological benefits in survivors are lacking [64]. Therefore, sPIF may provide a safe and effective therapy to not only to reduce PTB or fetal loss [20] but may modulate neuronal migration/development in these infants at high-risk [35,36].

Finally, we acknowledge that the current study has some minor limitation. The primary limitation of the study is the lack of functional outcomes in the offspring. Although we did not provide functional testing, we show modulation of neuronal progenitors and microglial cells of the fetuses and our results are in line with previous evidence of sPIF neuroprotective properties [33,35,36,49,50]. Further studies will address sPIF's impact during fetal brain development. We further acknowledge that we didn't provide detailed insights to potential pathways involved in immune modulation or neuronal regulation. We provide evidence that sPIF prevents PTB efficiently and additional analyses including response not only bacterial but also viral challenges are ongoing but beyond the scope of this manuscript.

In conclusion, we provide evidence that sPIF is a potential therapeutic (targeted prophylaxis) in inflammatory induced PTB. These results are in line with sPIF's efficacy previously observed in several preclinical models of immune disorders [20,32–38]. Importantly, this is the first description of sPIF restoring PTB related morbidities such as fetal brain development. Given that sPIF finished first-in-human Phase Ib clinical trial (NCT02239562), sPIF therapy in pregnancy disorders such as preeclampsia, early pregnancy loss, and fetal loss can be envisioned [20,21,27].

Author Contributions

Conceptualization: Marialuigia Spinelli, Roberta Castellani, Giovanni Scambia, Eytan R. Barnea, Daniel Surbek, Martin Mueller, Nicoletta Di Simone.

Data curation: Marialuigia Spinelli, Céline Boucard, Valerie Haesler, Nicoletta Di Simone.

Formal analysis: Marialuigia Spinelli, Nicoletta Di Simone.

Funding acquisition: Giovanni Scambia, Eytan R. Barnea, Daniel Surbek, Martin Mueller.

Investigation: Marialuigia Spinelli, Céline Boucard, Valerie Haesler, Eytan R. Barnea, Nicoletta Di Simone.

Methodology: Marialuigia Spinelli, Céline Boucard, Fiorella Di Nicuolo, Martin Mueller, Nicoletta Di Simone.

Project administration: Roberta Castellani, Eytan R. Barnea, Daniel Surbek, Martin Mueller.

Resources: Valerie Haesler, Roberta Castellani, Alfredo Pontecorvi, Giovanni Scambia, Eytan R. Barnea, Daniel Surbek.

Software: Fiorella Di Nicuolo, Alfredo Pontecorvi, Chiara Granieri, Eytan R. Barnea.

Supervision: Daniel Surbek, Martin Mueller.

Validation: Alfredo Pontecorvi, Giovanni Scambia, Chiara Granieri.

Visualization: Roberta Castellani, Chiara Granieri.

Writing – original draft: Marialuigia Spinelli, Martin Mueller, Nicoletta Di Simone.

Writing – review & editing: Marialuigia Spinelli, Martin Mueller, Nicoletta Di Simone.

References

1. Harrison MS, Goldenberg RL (2016) Global burden of prematurity. *Semin Fetal Neonatal Med* 21: 74–79. <https://doi.org/10.1016/j.siny.2015.12.007> PMID: 26740166
2. Boyle AK, Rinaldi SF, Norman JE, Stock SJ (2017) Preterm birth: Inflammation, fetal injury and treatment strategies. *J Reprod Immunol* 119: 62–66. <https://doi.org/10.1016/j.jri.2016.11.008> PMID: 28122664
3. Chu DM, Seferovic M, Pace RM, Aagaard KM (2018) The microbiome in preterm birth. *Best Pract Res Clin Obstet Gynaecol* 52: 103–113. <https://doi.org/10.1016/j.bpobgyn.2018.03.006> PMID: 29753695
4. Dunn AB, Dunlop AL, Hogue CJ, Miller A, Corwin EJ (2017) The Microbiome and Complement Activation: A Mechanistic Model for Preterm Birth. *Biol Res Nurs* 19: 295–307. <https://doi.org/10.1177/1099800416687648> PMID: 28073296
5. Lu HY, Zhang Q, Wang QX, Lu JY (2016) Contribution of Histologic Chorioamnionitis and Fetal Inflammatory Response Syndrome to Increased Risk of Brain Injury in Infants With Preterm Premature Rupture of Membranes. *Pediatr Neurol* 61: 94–98 e91. <https://doi.org/10.1016/j.pediatrneurol.2016.05.001> PMID: 27353694
6. Been JV, Lievens S, Zimmermann LJ, Kramer BW, Wolfs TG (2013) Chorioamnionitis as a risk factor for necrotizing enterocolitis: a systematic review and meta-analysis. *J Pediatr* 162: 236–242 e232. <https://doi.org/10.1016/j.jpeds.2012.07.012> PMID: 22920508
7. Park HW, Choi YS, Kim KS, Kim SN (2015) Chorioamnionitis and Patent Ductus Arteriosus: A Systematic Review and Meta-Analysis. *PLoS One* 10: e0138114. <https://doi.org/10.1371/journal.pone.0138114> PMID: 26375582
8. Smith AL, Alexander M, Rosenkrantz TS, Sadek ML, Fitch RH (2014) Sex differences in behavioral outcome following neonatal hypoxia ischemia: insights from a clinical meta-analysis and a rodent model of induced hypoxic ischemic brain injury. *Exp Neurol* 254: 54–67. <https://doi.org/10.1016/j.expneurol.2014.01.003> PMID: 24434477
9. Padilla N, Eklöf E, Mårtensson GE, Bölte S, Lagercrantz H, et al. (2015) Poor Brain Growth in Extremely Preterm Neonates Long Before the Onset of Autism Spectrum Disorder Symptoms. *Cereb Cortex*.

10. Clark DA (2016) The importance of being a regulatory T cell in pregnancy. *J Reprod Immunol* 116: 60–69. <https://doi.org/10.1016/j.jri.2016.04.288> PMID: 27219894
11. PrabhuDas M, Bonney E, Caron K, Dey S, Erlebacher A, et al. (2015) Immune mechanisms at the maternal-fetal interface: perspectives and challenges. *Nat Immunol* 16: 328–334. <https://doi.org/10.1038/ni.3131> PMID: 25789673
12. Gomez-Lopez N, Motomura K, Miller D, Garcia-Flores V, Galaz J, et al. (2019) Inflammasomes: Their Role in Normal and Complicated Pregnancies. *J Immunol* 203: 2757–2769. <https://doi.org/10.4049/jimmunol.1900901> PMID: 31740550
13. D'Ippolito S, Tersigni C, Marana R, Di Nicuolo F, Gaglione R, et al. (2016) Inflammasome in the human endometrium: further step in the evaluation of the "maternal side". *Fertil Steril* 105: 111–118 e111–114. <https://doi.org/10.1016/j.fertnstert.2015.09.027> PMID: 26474737
14. Dunne A (2011) Inflammasome activation: from inflammatory disease to infection. *Biochem Soc Trans* 39: 669–673. <https://doi.org/10.1042/BST0390669> PMID: 21428959
15. Boyle AK, Rinaldi SF, Rossi AG, Saunders PTK, Norman JE (2019) Repurposing simvastatin as a therapy for preterm labor: evidence from preclinical models. *FASEB J* 33: 2743–2758. <https://doi.org/10.1096/fj.201801104R> PMID: 30312114
16. Rossol M, Heine H, Meusch U, Quandt D, Klein C, et al. (2011) LPS-induced cytokine production in human monocytes and macrophages. *Crit Rev Immunol* 31: 379–446. <https://doi.org/10.1615/critrevimmunol.v31.i5.20> PMID: 22142165
17. Clark DA (2008) Immunological factors in pregnancy wastage: fact or fiction. *Am J Reprod Immunol* 59: 277–300. <https://doi.org/10.1111/j.1600-0897.2008.00580.x> PMID: 18336385
18. Moffett-King A (2002) Natural killer cells and pregnancy. *Nat Rev Immunol* 2: 656–663. <https://doi.org/10.1038/nri886> PMID: 12209134
19. Barnea ER (2007) Applying embryo-derived immune tolerance to the treatment of immune disorders. *Ann N Y Acad Sci* 1110: 602–618. <https://doi.org/10.1196/annals.1423.064> PMID: 17911476
20. Di Simone N, Di Nicuolo F, Marana R, Castellani R, Ria F, et al. (2017) Synthetic Preimplantation Factor (PIF) prevents fetal loss by modulating LPS induced inflammatory response. *PLoS One* 12: e0180642. <https://doi.org/10.1371/journal.pone.0180642> PMID: 28704412
21. Barnea ER, Almogi-Hazan O, Or R, Mueller M, Ria F, et al. (2015) Immune regulatory and neuroprotective properties of preimplantation factor: From newborn to adult. *Pharmacol Ther* 156: 10–25. <https://doi.org/10.1016/j.pharmthera.2015.10.008> PMID: 26546485
22. Moindjie H, Santos ED, Loeuillet L, Gronier H, de Mazancourt P, et al. (2014) Preimplantation factor (PIF) promotes human trophoblast invasion. *Biol Reprod* 91: 118. <https://doi.org/10.1095/biolreprod.114.119156> PMID: 25232018
23. Ramu S, Stamatkin C, Timms L, Ruble M, Roussev RG, et al. (2013) Preimplantation factor (PIF) detection in maternal circulation in early pregnancy correlates with live birth (bovine model). *Reprod Biol Endocrinol* 11: 105. <https://doi.org/10.1186/1477-7827-11-105> PMID: 24238492
24. Paidas MJ, Krikun G, Huang SJ, Jones R, Romano M, et al. (2010) A genomic and proteomic investigation of the impact of preimplantation factor on human decidual cells. *Am J Obstet Gynecol* 202: 459 e451–458.
25. Duzjy CM, Barnea ER, Li M, Huang SJ, Krikun G, et al. (2010) Preimplantation factor promotes first trimester trophoblast invasion. *Am J Obstet Gynecol* 203: 402 e401–404.
26. Barnea ER, Kirk D, Paidas MJ (2012) Preimplantation factor (PIF) promoting role in embryo implantation: increases endometrial integrin- α 2 β 3, amphiregulin and epiregulin while reducing betacellulin expression via MAPK in decidua. *Reprod Biol Endocrinol* 10: 50. <https://doi.org/10.1186/1477-7827-10-50> PMID: 22788113
27. Barnea ER, Vialard F, Moindjie H, Ornaghi S, Dieudonne MN, et al. (2016) Preimplantation Factor (PIF*) endogenously prevents preeclampsia: Promotes trophoblast invasion and reduces oxidative stress. *J Reprod Immunol* 114: 58–64. <https://doi.org/10.1016/j.jri.2015.06.002> PMID: 26257082
28. Stamatkin CW, Roussev RG, Stout M, Coulam CB, Triche E, et al. (2011) Preimplantation factor negates embryo toxicity and promotes embryo development in culture. *Reprod Biomed Online* 23: 517–524. <https://doi.org/10.1016/j.rbmo.2011.06.009> PMID: 21900046
29. Barnea ER, Lubman DM, Liu YH, Absalon-Medina V, Hayrabyan S, et al. (2014) Insight into Preimplantation Factor (PIF*) mechanism for embryo protection and development: target oxidative stress and protein misfolding (PDI and HSP) through essential RIKP [corrected] binding site. *PLoS One* 9: e100263. <https://doi.org/10.1371/journal.pone.0100263> PMID: 24983882
30. Barnea ER, Kirk D, Ramu S, Rivnay B, Roussev R, et al. (2012) Preimplantation Factor (PIF) orchestrates systemic antiinflammatory response by immune cells: effect on peripheral blood mononuclear

- cells. *Am J Obstet Gynecol* 207: 313 e311–311. <https://doi.org/10.1016/j.ajog.2012.07.017> PMID: 23021695
31. Roussev RG, Dons'koi BV, Stamatkin C, Ramu S, Chernyshov VP, et al. (2013) Preimplantation factor inhibits circulating natural killer cell cytotoxicity and reduces CD69 expression: implications for recurrent pregnancy loss therapy. *Reprod Biomed Online* 26: 79–87. <https://doi.org/10.1016/j.rbmo.2012.09.017> PMID: 23186554
 32. Weiss L, Bernstein S, Jones R, Amunugama R, Krizman D, et al. (2011) Preimplantation factor (PIF) analog prevents type I diabetes mellitus (T1DM) development by preserving pancreatic function in NOD mice. *Endocrine* 40: 41–54. <https://doi.org/10.1007/s12020-011-9438-5> PMID: 21424847
 33. Weiss L, Or R, Jones RC, Amunugama R, JeBailey L, et al. (2012) Preimplantation factor (PIF*) reverses neuroinflammation while promoting neural repair in EAE model. *J Neurol Sci* 312: 146–157. <https://doi.org/10.1016/j.jns.2011.07.050> PMID: 21996270
 34. Azar Y, Shainer R, Almogi-Hazan O, Bringer R, Compton SR, et al. (2013) Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model). *Biol Blood Marrow Transplant* 19: 519–528. <https://doi.org/10.1016/j.bbmt.2012.12.011> PMID: 23266739
 35. Mueller M, Zhou J, Yang L, Gao Y, Wu F, et al. (2014) Preimplantation factor promotes neuroprotection by targeting microRNA let-7. *Proc Natl Acad Sci U S A* 111: 13882–13887. <https://doi.org/10.1073/pnas.1411674111> PMID: 25205808
 36. Mueller M, Schoeberlein A, Zhou J, Joergers-Messerli M, Oppliger B, et al. (2015) Preimplantation Factor bolsters neuroprotection via modulating Protein Kinase A and Protein Kinase C signaling. *Cell Death Differ* 22: 2078–2086. <https://doi.org/10.1038/cdd.2015.55> PMID: 25976303
 37. Chen YC, Rivera J, Fitzgerald M, Hausding C, Ying YL, et al. (2016) Preimplantation factor prevents atherosclerosis via its immunomodulatory effects without affecting serum lipids. *Thromb Haemost* 115: 1010–1024. <https://doi.org/10.1160/TH15-08-0640> PMID: 26842698
 38. Shainer R, Almogi-Hazan O, Berger A, Hinden L, Mueller M, et al. (2016) Preimplantation factor (PIF) therapy provides comprehensive protection against radiation induced pathologies. *Oncotarget*.
 39. Sizonenko SV, Sirimanne E, Mayall Y, Gluckman PD, Inder T, et al. (2003) Selective cortical alteration after hypoxic-ischemic injury in the very immature rat brain. *Pediatr Res* 54: 263–269. <https://doi.org/10.1203/01.PDR.0000072517.01207.87> PMID: 12736386
 40. Sizonenko SV, Kiss JZ, Inder T, Gluckman PD, Williams CE (2005) Distinctive neuropathologic alterations in the deep layers of the parietal cortex after moderate ischemic-hypoxic injury in the P3 immature rat brain. *Pediatr Res* 57: 865–872. <https://doi.org/10.1203/01.PDR.0000157673.36848.67> PMID: 15774844
 41. Yamada M, Clark J, McClelland C, Capaldo E, Ray A, et al. (2015) Cux2 activity defines a subpopulation of perinatal neurogenic progenitors in the hippocampus. *Hippocampus* 25: 253–267. <https://doi.org/10.1002/hipo.22370> PMID: 25252086
 42. Fregoso SP, Dwyer BE, Franco SJ (2019) Lmx1a drives Cux2 expression in the cortical hem through activation of a conserved intronic enhancer. *Development* 146.
 43. Ofengeim D, Chen YB, Miyawaki T, Li H, Sacchetti S, et al. (2012) N-terminally cleaved Bcl-xL mediates ischemia-induced neuronal death. *Nat Neurosci* 15: 574–580. <https://doi.org/10.1038/nn.3054> PMID: 22366758
 44. Jellema RK, Lima Passos V, Zwanenburg A, Ophelders DR, De Munter S, et al. (2013) Cerebral inflammation and mobilization of the peripheral immune system following global hypoxia-ischemia in preterm sheep. *J Neuroinflammation* 10: 13. <https://doi.org/10.1186/1742-2094-10-13> PMID: 23347579
 45. Silver RM, Edwin SS, Umar F, Dudley DJ, Branch DW, et al. (1997) Bacterial lipopolysaccharide-mediated murine fetal death: the role of interleukin-1. *Am J Obstet Gynecol* 176: 544–549. [https://doi.org/10.1016/s0002-9378\(97\)70545-3](https://doi.org/10.1016/s0002-9378(97)70545-3) PMID: 9077604
 46. Robertson SA, Care AS, Skinner RJ (2007) Interleukin 10 regulates inflammatory cytokine synthesis to protect against lipopolysaccharide-induced abortion and fetal growth restriction in mice. *Biol Reprod* 76: 738–748. <https://doi.org/10.1095/biolreprod.106.056143> PMID: 17215490
 47. Hansen-Pupp I, Harling S, Berg AC, Cilio C, Hellstrom-Westas L, et al. (2005) Circulating interferon-gamma and white matter brain damage in preterm infants. *Pediatr Res* 58: 946–952. <https://doi.org/10.1203/01.PDR.0000182592.76702.E8> PMID: 16183810
 48. Erta M, Quintana A, Hidalgo J (2012) Interleukin-6, a major cytokine in the central nervous system. *Int J Biol Sci* 8: 1254–1266. <https://doi.org/10.7150/ijbs.4679> PMID: 23136554
 49. Migliara G, Mueller M, Piermattei A, Brodie C, Paidas MJ, et al. (2017) PIF* promotes brain re-myelination locally while regulating systemic inflammation- clinically relevant multiple sclerosis M.smeigmatis model. *Oncotarget* 8: 21834–21851. <https://doi.org/10.18632/oncotarget.15662> PMID: 28423529

50. Hayrabedian S, Shainer R, Yekhtin Z, Weiss L, Almogi-Hazan O, et al. (2019) Synthetic PreImplantation Factor (sPIF) induces posttranslational protein modification and reverses paralysis in EAE mice. *Sci Rep* 9: 12876. <https://doi.org/10.1038/s41598-019-48473-x> PMID: 31578341
51. Lappas M, McCracken S, McKelvey K, Lim R, James J, et al. (2018) Formyl peptide receptor-2 is decreased in foetal growth restriction and contributes to placental dysfunction. *Mol Hum Reprod* 24: 94–109. <https://doi.org/10.1093/molehr/gax067> PMID: 29272530
52. Li J, Ding Z, Yang Y, Mao B, Wang Y, et al. (2018) Lycium barbarum polysaccharides protect human trophoblast HTR8/SVneo cells from hydrogen peroxide-induced oxidative stress and apoptosis. *Mol Med Rep* 18: 2581–2588. <https://doi.org/10.3892/mmr.2018.9274> PMID: 30015960
53. Fernandez-Calle R, Vicente-Rodriguez M, Gramage E, Pita J, Perez-Garcia C, et al. (2017) Pleiotrophin regulates microglia-mediated neuroinflammation. *J Neuroinflammation* 14: 46. <https://doi.org/10.1186/s12974-017-0823-8> PMID: 28259175
54. Hanisch UK (2002) Microglia as a source and target of cytokines. *Glia* 40: 40–55.
55. Hagberg H, Gressens P, Mallard C (2012) Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. *Ann Neurol* 71: 444–457. <https://doi.org/10.1002/ana.22620> PMID: 22334391
56. Baron JC, Yamauchi H, Fujioka M, Endres M (2014) Selective neuronal loss in ischemic stroke and cerebrovascular disease. *J Cereb Blood Flow Metab* 34: 2–18. <https://doi.org/10.1038/jcbfm.2013.188> PMID: 24192635
57. Ortinau C, Neil J (2015) The neuroanatomy of prematurity: normal brain development and the impact of preterm birth. *Clin Anat* 28: 168–183. <https://doi.org/10.1002/ca.22430> PMID: 25043926
58. Molyneaux BJ, Arlotta P, Menezes JR, Macklis JD (2007) Neuronal subtype specification in the cerebral cortex. *Nat Rev Neurosci* 8: 427–437. <https://doi.org/10.1038/nrn2151> PMID: 17514196
59. Kubo KI, Deguchi K, Nagai T, Ito Y, Yoshida K, et al. (2017) Association of impaired neuronal migration with cognitive deficits in extremely preterm infants. *JCI Insight* 2.
60. Cubelos B, Sebastian-Serrano A, Beccari L, Calcagnotto ME, Cisneros E, et al. (2010) Cux1 and Cux2 regulate dendritic branching, spine morphology, and synapses of the upper layer neurons of the cortex. *Neuron* 66: 523–535. <https://doi.org/10.1016/j.neuron.2010.04.038> PMID: 20510857
61. al. SA-Ne (2020) The Interplay Between Reproductive Tract Microbiota and Immunological System in Human Reproduction. *Front Immunol* in press.
62. Robertson RC, Manges AR, Finlay BB, Prendergast AJ (2019) The Human Microbiome and Child Growth—First 1000 Days and Beyond. *Trends Microbiol* 27: 131–147. <https://doi.org/10.1016/j.tim.2018.09.008> PMID: 30529020
63. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, et al. (2013) Cooling for newborns with hypoxic ischaemic encephalopathy. *Cochrane Database Syst Rev*: CD003311. <https://doi.org/10.1002/14651858.CD003311.pub3> PMID: 23440789
64. Doyle LW, Anderson PJ, Haslam R, Lee KJ, Crowther C, et al. (2014) School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. *JAMA* 312: 1105–1113. <https://doi.org/10.1001/jama.2014.11189> PMID: 25226476